Here’s What Hurt Boston Scientific Corporation (BSX) in Q2

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large ...

Is UGI’s (UGI) Utility Win Enough To Offset Propane Pain?

UGI (NYSE:UGI) walked into its fiscal 2026 third-quarter earnings call on August 6 with a split story to tell.
Insider Monkey

Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?

The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the ...
Insider Monkey

Could Dutch Bros (BROS)’ Salad and Go Deal Fuel Its Next Wave of Growth?

Dutch Bros Inc. (NYSE:BROS) announced on August 5 an agreement to acquire the real estate and site assets of up to 65 Salad and Go drive-thru locations across Arizona, Nevada, Oklahoma, and Texas. The ...
Insider Monkey

Could HCA Healthcare, Inc. (HCA) Stock Rebound After Guidance Cuts and Payer Pressure?

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible ...
Insider Monkey

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20).
Insider Monkey

e.l.f Beauty, Inc. (ELF) Crushes Q1 2027 Estimates as Rhode Fuels a Major Growth Acceleration

Pre-earnings options volume in e.l.f Beauty, Inc. (NYSE:ELF) traded at 1.2x normal levels on August 5, with calls leading puts 8:7. Implied volatility suggested traders were anticipating a ...
Insider Monkey

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is ...
Insider Monkey

Doximity Doubled, Then Gave Most of It Back. Here’s Why the Market Doesn’t Trust the Rally

For a few hours on August 7, Doximity, Inc. (NYSE:DOCS) appeared to be the story of the earnings season. The medical-networking platform’s stock more than doubled overnight following its fiscal ...

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

According to reports, 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million.
Insider Monkey

AI Data Centers Are Running Out of Water. This $6 Stock Has a Fix

Major AI stocks are getting expensive and everyday investors are in search of low-priced names that have the potential to return huge profits in the long term. To find where smart retail investors are ...
Insider Monkey

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s ...